We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) closed at $72.99 in the latest trading session, marking a +1.08% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.57% for the day. Meanwhile, the Dow experienced a drop of 1.61%, and the technology-dominated Nasdaq saw a decrease of 0.26%.
Prior to today's trading, shares of the medical device manufacturer had lost 4.36% lagged the Medical sector's gain of 0.06% and the S&P 500's loss of 0.15%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. On that day, Boston Scientific is projected to report earnings of $0.8 per share, which would represent year-over-year growth of 6.67%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.19 billion, up 11.32% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.46 per share and a revenue of $22.31 billion, signifying shifts of +13.07% and +11.11%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Boston Scientific. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.41% upward. Boston Scientific is currently a Zacks Rank #3 (Hold).
In terms of valuation, Boston Scientific is presently being traded at a Forward P/E ratio of 20.88. This expresses a premium compared to the average Forward P/E of 20.25 of its industry.
Investors should also note that BSX has a PEG ratio of 1 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products industry currently had an average PEG ratio of 1.74 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 136, this industry ranks in the bottom 45% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
Boston Scientific (BSX - Free Report) closed at $72.99 in the latest trading session, marking a +1.08% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.57% for the day. Meanwhile, the Dow experienced a drop of 1.61%, and the technology-dominated Nasdaq saw a decrease of 0.26%.
Prior to today's trading, shares of the medical device manufacturer had lost 4.36% lagged the Medical sector's gain of 0.06% and the S&P 500's loss of 0.15%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. On that day, Boston Scientific is projected to report earnings of $0.8 per share, which would represent year-over-year growth of 6.67%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.19 billion, up 11.32% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.46 per share and a revenue of $22.31 billion, signifying shifts of +13.07% and +11.11%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Boston Scientific. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.41% upward. Boston Scientific is currently a Zacks Rank #3 (Hold).
In terms of valuation, Boston Scientific is presently being traded at a Forward P/E ratio of 20.88. This expresses a premium compared to the average Forward P/E of 20.25 of its industry.
Investors should also note that BSX has a PEG ratio of 1 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products industry currently had an average PEG ratio of 1.74 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 136, this industry ranks in the bottom 45% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.